Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kunal Nepali

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Bioorganic & Medicinal Chemistry|March 1, 2011
A rational approach for the design and synthesis of 1-acetyl-3,5-diaryl-4,5-dihydro(1H)pyrazoles as a new class of potential non-purine xanthine oxidase inhibitorsKunal Nepali, Gurinderdeep Singh, Anil Turan, et al.
European Journal of Medicinal Chemistry|July 20, 2022
Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrierRam Sharma, Esha Chatterjee, Jacob Mathew, et al.
Organic & Biomolecular Chemistry|December 24, 2015
2-Aroylquinoline-5,8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (HSP90) inhibitionKunal Nepali, Sunil Kumar, Hsiang-Ling Huang, et al.
Organic & Biomolecular Chemistry|June 16, 2018
Correction: 2-Aroylquinoline-5,8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (HSP90) inhibitionKunal Nepali, Sunil Kumar, Hsiang-Ling Huang, et al.
European Journal of Medicinal Chemistry|March 24, 2018
1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDACRitu Ojha, Han-Li Huang, Wei-Chun HuangFu, et al.
Journal of Medicinal Chemistry|January 29, 2024
First-in-Class Dual EZH2-HSP90 Inhibitor Eliciting Striking Antiglioblastoma Activity <i>In Vitro</i> and <i>In Vivo</i>Sachin Sharma, Shao-An Wang, Wen-Bin Yang, et al.
Frontiers in Pharmacology|June 20, 2025
Anticancer activity of RM-3-22: a TAZQ-based hydroxamic acid derivative targeting NSCLC in vitro and in vivoEssha Chatterjee, Ram Sharma, Biswajit Dey, et al.
Bioorganic Chemistry|October 7, 2025
Olaparib-Cediranib Hybrid as Dual PARP-VEGFR3 Inhibitor Elicits Antitumor Efficacy: Rational Design, Synthesis, Biological Evaluation and Construction of a Charge Convertible pH Responsive NanoformulationMandeep Rana, N VijayKamasewara Rao, Zih-Yao Yu, et al.
European Journal of Medicinal Chemistry|November 27, 2018
1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylaseMei-Jung Lai, Ritu Ojha, Mei-Hsiang Lin, et al.
European Journal of Medicinal Chemistry|December 16, 2019
Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairmentNavdeep Kaur, Yao-Ching Fang, Hsueh-Yun Lee, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Bioorganic & Medicinal Chemistry|March 1, 2011
A rational approach for the design and synthesis of 1-acetyl-3,5-diaryl-4,5-dihydro(1H)pyrazoles as a new class of potential non-purine xanthine oxidase inhibitorsKunal Nepali, Gurinderdeep Singh, Anil Turan, et al.
European Journal of Medicinal Chemistry|July 20, 2022
Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrierRam Sharma, Esha Chatterjee, Jacob Mathew, et al.
Organic & Biomolecular Chemistry|December 24, 2015
2-Aroylquinoline-5,8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (HSP90) inhibitionKunal Nepali, Sunil Kumar, Hsiang-Ling Huang, et al.
Organic & Biomolecular Chemistry|June 16, 2018
Correction: 2-Aroylquinoline-5,8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (HSP90) inhibitionKunal Nepali, Sunil Kumar, Hsiang-Ling Huang, et al.
European Journal of Medicinal Chemistry|March 24, 2018
1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDACRitu Ojha, Han-Li Huang, Wei-Chun HuangFu, et al.
Journal of Medicinal Chemistry|January 29, 2024
First-in-Class Dual EZH2-HSP90 Inhibitor Eliciting Striking Antiglioblastoma Activity <i>In Vitro</i> and <i>In Vivo</i>Sachin Sharma, Shao-An Wang, Wen-Bin Yang, et al.
Frontiers in Pharmacology|June 20, 2025
Anticancer activity of RM-3-22: a TAZQ-based hydroxamic acid derivative targeting NSCLC in vitro and in vivoEssha Chatterjee, Ram Sharma, Biswajit Dey, et al.
Bioorganic Chemistry|October 7, 2025
Olaparib-Cediranib Hybrid as Dual PARP-VEGFR3 Inhibitor Elicits Antitumor Efficacy: Rational Design, Synthesis, Biological Evaluation and Construction of a Charge Convertible pH Responsive NanoformulationMandeep Rana, N VijayKamasewara Rao, Zih-Yao Yu, et al.
European Journal of Medicinal Chemistry|November 27, 2018
1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylaseMei-Jung Lai, Ritu Ojha, Mei-Hsiang Lin, et al.
European Journal of Medicinal Chemistry|December 16, 2019
Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairmentNavdeep Kaur, Yao-Ching Fang, Hsueh-Yun Lee, et al.
Pageof 9